News

MediciNova and the Hercules Market of the Osaka Securities Exchange have reported the proposed final protocol for phase II clinical trial (MN-221-CL-007). The trial will evaluate the safety

Bayer Schering has reported positive results for the phase-II study of the novel positron emission tomography (PET) tracer florbetaben (BAY 94-9172). The study showed that patients with Alzheimer’s

IVAX has signed a distribution agreement with Augurix for Simtomax Blood Drop, a test that diagnoses celiac disease in all patients. As part of the agreement, IVAX will

Abraxis has completed patient enrollment of a pivotal, phase III clinical study. The study compares the Abraxane for injectable suspension with Taxol (paclitaxel) injection, both in combination with

The Perrigo has received approval from the FDA to market over-the-counter coated nicotine polacrilex lozenge USP, 2mg and 4mg in cherry and cinnamon flavors. The company said that

Baxter and Flamel Technologies have entered into an agreement to formulate controlled release applications of blood clotting factor replacement therapies, using Flamel’s Medusa Technology. The two companies will

Victory Pharma (Victory) has reported that the US Food and Drug Administration (FDA) has accepted the company’ New Drug Application (NDA) for MGX006, for review. The company said

California-based Finesse Solutions has formed a development agreement with Biogen Idec, aimed at evaluating emerging technologies for single-use bioprocessing. These technologies include novel disposable sensors, software platforms, and

Phase Forward has announced that its InForm electronic data capture (EDC) solution has been utilized in more than 3,000 live or completed clinical trials to date with end